The Rapidly Evolving Landscape of Cellular and Immune-based Therapies When Henry Ford unveiled the Model T in 1908, the automobile industry was forever changed. A similar transformation is now underway in rheumatology, where cellular and immune therapies are redefining how we https://t.co/RQuVETSTG4

💬 #ACR25 Topic Panels — LIVE! Nov. 3 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology: 👉 RA Join Us Live on: X • Facebook • YouTube • LinkedIn • https://t.co/V10S4oVFsv Top experts. Real clinical insight. Don't miss these discussions https://t.co/i5UM0OBu86

• Home | RheumNow

#ACR25 - Day 1 Report https://t.co/JayJCP9Rue https://t.co/B62mKbW4B8

• ACR25 - Day 1 Report | RheumNow

"Personally I'm always ready to learn, although I do not always like being taught." – Winston Churchill

Catching AxSpA Early: Closing the Diagnostic Gap Dr. Akhil Sood reports on abstract 2635 and abstract 2636 presented at #ACR25. https://t.co/TmJQKQUu9E https://t.co/6dWf8DY2W3

• Catching AxSpA Early: Closing the Diagnostic Gap | RheumNow

RA: Inject the Steroids Dr. Richard Conway reports on abstract 1355, "Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance of being off steroids and escalation of therapy at 1 year," presented at the #ACR25. https://t.co/xFQMIpi75S

#ACR25 Best Abstracts - Day 1 The RheumNow Faculty have run through day one at ACR25 and come with a few of their favorites - some what you expect, but some of these are gems. https://t.co/tYY5xGOEGU https://t.co/wpQbvEcH1f

• ACR25 Best Abstracts - Day 1 | RheumNow

New Gout Therapies Show Promise in Phase III Trials At #ACR25, the American College of Rheumatology’s annual meeting, researchers presented pivotal Phase III studies highlighting novel therapeutic options for patients with gout, particularly those with limited treatment choices https://t.co/Ff16L2CHc0

#ACR25 Sheds Light on Disparities, Age-Related Trends, and Epidemiology in Autoimmune Rheumatic Diseases At #ACR25, new research explored critical disparities and epidemiologic trends shaping outcomes in autoimmune rheumatic diseases across diverse populations and age groups. https://t.co/CPob0ppjv3

💬 #ACR2025 Topic Panels — LIVE! Nov. 2 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology: 👉 PsA Join Us Live on: X Live • Facebook Live • YouTube Live • LinkedIn Live • https://t.co/V10S4oVFsv Top experts. Real clinical insight. Don't miss https://t.co/A4pUjZG3Dr

• Home | RheumNow

Upadacitinib is a Double Edged Vascular Sword in GCA Dr. David Liew discusses abstracts O751, O738, and O734 presented at #ACR25. https://t.co/eTmVehP2Cd https://t.co/vxehwRWM2D

• Upadacitinib is a Double Edged Vascular Sword in GCA | RheumNow